Require health plan and Medicaid coverage of biomarker testing

HB 24 requires private health plans and Medicaid in Ohio to cover biomarker testing for diagnosis, treatment management, and ongoing monitoring of diseases, provided the test is deemed medically necessary by a qualified healthcare provider. The bill mandates that coverage decisions be based on established medical evidence, such as FDA labels, federal coverage determinations, or nationally recognized clinical guidelines, while explicitly excluding coverage for screening purposes. To ensure patient care is not disrupted, the legislation also requires that coverage be structured to minimize the need for multiple biopsies or sample collections. Additionally, the law establishes an accessible appeal process for coverage determinations and includes language intended to prevent significant price increases for these tests.